Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $180 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Brandon Folkes has reiterated an Overweight rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and maintained a price target of $180.
August 22, 2023 | 1:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Jazz Pharmaceuticals and maintained a price target of $180.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Jazz Pharmaceuticals. The maintained price target of $180 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100